CLINICAL TRIALS PROFILE FOR TECHNETIUM TC 99M SESTAMIBI

All Clinical Trials for TECHNETIUM TC 99M SESTAMIBI

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00767468 ↗	Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis	Terminated	National Cancer Institute (NCI)	Phase 1	2008-10-01	RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of sorafenib in treating patients with locally advanced or metastatic liver cancer and cirrhosis.
NCT00767468 ↗	Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis	Terminated	UNC Lineberger Comprehensive Cancer Center	Phase 1	2008-10-01	RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of sorafenib in treating patients with locally advanced or metastatic liver cancer and cirrhosis.
NCT00560495 ↗	Radiation Therapy and Ammonium Tetrathiomolybdate in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer	Withdrawn	National Cancer Institute (NCI)	Phase 1	2007-05-01	RATIONALE: Ammonium tetrathiomolybdate may stop the growth of non-small cell lung cancer by blocking blood flow to the tumor. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving ammonium tetrathiomolybdate together with radiation therapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects of giving radiation therapy together with ammonium tetrathiomolybdate in treating patients with stage I, stage II, or stage III non-small cell lung cancer.
NCT00560495 ↗	Radiation Therapy and Ammonium Tetrathiomolybdate in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer	Withdrawn	Roswell Park Cancer Institute	Phase 1	2007-05-01	RATIONALE: Ammonium tetrathiomolybdate may stop the growth of non-small cell lung cancer by blocking blood flow to the tumor. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving ammonium tetrathiomolybdate together with radiation therapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects of giving radiation therapy together with ammonium tetrathiomolybdate in treating patients with stage I, stage II, or stage III non-small cell lung cancer.
NCT00162071 ↗	A Phase II Optimization Study of BMS068645 and Sestamibi Planar Imaging	Terminated	Forest Laboratories	Phase 2	2005-07-01	The primary purpose of this study is to determine the optimal time for myocardial perfusion imaging with Technetium Tc99m Sestamibi following the administration of BMS068645. The safety of BMS068645 will also be studied.
NCT00162045 ↗	A Trial to Determine Radiation Exposure to Organs and Assess the Safety of CARDIOLITE® in Pediatric Subjects	Completed	Lantheus Medical Imaging	Phase 1/Phase 2	2005-01-01	The purpose of this Phase I-II multicenter clinical trial is to establish dosimetry and safety profiles for CARDIOLITE® (Technetium Tc99m Sestamibi) in pediatric subjects.

Clinical Trial Conditions for TECHNETIUM TC 99M SESTAMIBI

Condition Name

Condition Name for TECHNETIUM TC 99M SESTAMIBI
Intervention	Trials
Estrogen Receptor Negative	1
HER2/Neu Negative	1
Ischemic Heart Disease	1
Kawasaki Disease	1

Condition MeSH

Condition MeSH for TECHNETIUM TC 99M SESTAMIBI
Intervention	Trials
Syndrome	2
Breast Neoplasms	1
Mucocutaneous Lymph Node Syndrome	1
Lung Neoplasms	1

Clinical Trial Locations for TECHNETIUM TC 99M SESTAMIBI

Trials by Country

+

−

Trials by Country for TECHNETIUM TC 99M SESTAMIBI
Location	Trials
United States	13
Taiwan	1
Canada	1

Trials by US State

+

−

Trials by US State for TECHNETIUM TC 99M SESTAMIBI
Location	Trials
Minnesota	2
New York	2
Washington	1
South Carolina	1
Pennsylvania	1

Clinical Trial Progress for TECHNETIUM TC 99M SESTAMIBI

Clinical Trial Phase

Clinical Trial Phase for TECHNETIUM TC 99M SESTAMIBI
Clinical Trial Phase	Trials
Phase 4	1
Phase 2	2
Phase 1/Phase 2	1

Clinical Trial Status

Clinical Trial Status for TECHNETIUM TC 99M SESTAMIBI
Clinical Trial Phase	Trials
Completed	3
Terminated	2
Recruiting	1

Clinical Trial Sponsors for TECHNETIUM TC 99M SESTAMIBI

Sponsor Name

Sponsor Name for TECHNETIUM TC 99M SESTAMIBI
Sponsor	Trials
National Cancer Institute (NCI)	3
Mayo Clinic	2
Lantheus Medical Imaging	1

Sponsor Type

Sponsor Type for TECHNETIUM TC 99M SESTAMIBI
Sponsor	Trials
NIH	5
Other	5
Industry	3

Technetium Tc 99m Sestamibi: Clinical Trials, Market Analysis, and Projections

Introduction

Technetium Tc 99m Sestamibi is a versatile radiopharmaceutical widely used in medical imaging, particularly for diagnosing and managing various cardiac and non-cardiac conditions. This article provides an update on current clinical trials, market analysis, and future projections for this essential diagnostic tool.

Clinical Trials Update

Myocardial Perfusion Imaging

Technetium Tc 99m Sestamibi is predominantly used for myocardial perfusion imaging to detect coronary artery disease, myocardial ischemia, and infarction. Clinical trials continue to validate its efficacy in these applications. For instance, the drug is used in rest and stress imaging protocols to evaluate myocardial function and guide patient management decisions[1].

Non-Cardiac Applications

Beyond cardiac imaging, Technetium Tc 99m Sestamibi is also being explored in other clinical contexts. A notable example is the use of Technetium Tc 99m Sestamibi SPECT/CT in evaluating kidney tumors. This trial aims to assess the effectiveness of SPECT/CT in clinical decision-making for patients with kidney neoplasms, offering a less invasive alternative to traditional diagnostic methods[4].

Breast Imaging

Technetium Tc 99m Sestamibi is indicated for planar imaging of breast lesions, particularly in cases where mammography results are abnormal or a palpable breast mass is present. Ongoing research continues to refine its use in this area, enhancing diagnostic accuracy and patient outcomes[1].

Market Analysis

Current Market Size and Growth

The Technetium-99m market, which includes Technetium Tc 99m Sestamibi, is experiencing significant growth. As of 2023, the market size was valued at approximately USD 4.95 billion and is projected to grow at a compound annual growth rate (CAGR) of 4.05% from 2024 to 2030, reaching nearly USD 6.54 billion by 2030[5].

Regional Market Dynamics

The market is geographically diverse, with North America, particularly the United States and Canada, holding a significant share due to advanced healthcare infrastructure and high prevalence of chronic diseases. Europe, especially countries like Germany, France, and the UK, also contribute substantially to the market. The Asia-Pacific region, including Japan, China, and India, is witnessing rapid growth driven by investments in healthcare infrastructure and an increasing focus on advanced diagnostics[3][5].

Application Segmentation

Technetium Tc 99m Sestamibi is utilized across various clinical applications, with cardiovascular imaging being the largest segment. This is due to its critical role in myocardial perfusion imaging, which assesses blood flow in the heart. Other significant applications include bone scans, respiratory imaging, and tumor imaging[5].

Market Projections

Future Outlook

The Technetium-99m market, including Technetium Tc 99m Sestamibi, is poised for continued growth. Several factors drive this projection:

• Advancements in Imaging Technology: Improvements in SPECT (Single Photon Emission Computed Tomography) and Gamma Cameras enhance the diagnostic capabilities of Technetium Tc 99m Sestamibi[3].
• Rising Healthcare Demands: Increasing prevalence of chronic and non-communicable diseases globally necessitates more accurate and reliable diagnostic tools[3].
• Expanding Healthcare Infrastructure: Investments in healthcare facilities, especially in emerging markets like China, India, and Latin America, are expected to boost demand for Technetium Tc 99m Sestamibi[3][5].

Cost-Effectiveness

Studies have compared the cost-effectiveness of Technetium Tc 99m Sestamibi with other radiopharmaceuticals like Thallium-201. While Thallium-201 may be more cost-effective in certain scenarios, especially with light patient scheduling, Technetium Tc 99m Sestamibi is more cost-effective in high-volume patient settings and when Thallium-201 is not used efficiently due to decay[2].

Key Players and Collaborations

The Technetium-99m market is characterized by an increasing focus on collaborations and mergers among key players. These partnerships aim to enhance product portfolios, improve supply chains, and invest in next-generation radiopharmaceuticals. Such collaborations are expected to drive market growth by ensuring the availability of high-quality Technetium Tc 99m Sestamibi and expanding its applications in new diagnostic areas[3].

Conclusion

Technetium Tc 99m Sestamibi remains a vital tool in medical diagnostics, particularly in cardiac and non-cardiac imaging. Ongoing clinical trials continue to validate its efficacy and explore new applications. The market for Technetium-99m, driven by advancements in imaging technology, rising healthcare demands, and expanding healthcare infrastructure, is projected to grow significantly over the next decade.

Key Takeaways

• Clinical Versatility: Technetium Tc 99m Sestamibi is used in various clinical applications, including myocardial perfusion imaging, breast imaging, and kidney tumor evaluation.
• Market Growth: The Technetium-99m market is expected to grow at a CAGR of 4.05% from 2024 to 2030, reaching nearly USD 6.54 billion by 2030.
• Regional Dynamics: North America, Europe, and the Asia-Pacific region are key markets, with emerging markets showing rapid growth.
• Cost-Effectiveness: Technetium Tc 99m Sestamibi is more cost-effective in high-volume patient settings compared to Thallium-201.
• Collaborations and Innovations: Market growth is driven by collaborations among key players and investments in next-generation radiopharmaceuticals.

FAQs

Q: What are the primary indications for Technetium Tc 99m Sestamibi?

Technetium Tc 99m Sestamibi is primarily indicated for detecting coronary artery disease by localizing myocardial ischemia and infarction, and for evaluating breast lesions after abnormal mammography or palpable breast masses[1].

Q: How is Technetium Tc 99m Sestamibi administered?

Technetium Tc 99m Sestamibi is administered intravenously, with suggested dose ranges varying between 370-1110 MBq (10-30 mCi) for myocardial imaging and 740-1110 MBq (20-30 mCi) for breast imaging[1].

Q: What are the advantages of using Technetium Tc 99m Sestamibi over Thallium-201?

Technetium Tc 99m Sestamibi is more cost-effective in high-volume patient settings and when Thallium-201 is not used efficiently due to decay. It also offers better imaging characteristics and is more suitable for SPECT imaging[2].

Q: What is the projected market size of Technetium-99m by 2030?

The Technetium-99m market is projected to reach nearly USD 6.54 billion by 2030, growing at a CAGR of 4.05% from 2024 to 2030[5].

Q: Which regions are driving the growth of the Technetium-99m market?

North America, Europe, and the Asia-Pacific region are key drivers of the Technetium-99m market, with emerging markets in Asia-Pacific showing rapid growth due to investments in healthcare infrastructure and increasing demand for advanced diagnostics[3][5].

Sources

1. Drugs.com: Technetium TC 99M Sestamibi: Package Insert / Prescribing Info.
2. Journal of Nuclear Medicine Technology: Cost-Effectiveness of Thallium-201 versus Technetium·99m· Sestamibi in the Detection of Coronary Artery Disease.
3. GlobeNewswire: Technetium-99m Market Poised for Growth, Projected to Reach Over US$ 8.6 Billion by 2034.
4. University of California Health: SPECT/CT for Kidney Tumors.
5. Maximize Market Research: Technetium-99m Market: Industry Analysis and Forecast 2030.